Skip to content

VectorXcellerator Programme: Fully funded feasibility studies to support early-stage cell and gene therapy programmes

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

OXB Logo_Navy_RGB
  • Home
  • CDMO solutions
    CDMO solutions
    • Process development
    • GMP manufacturing
    • Analytical methods
    • Regulatory support
    Viral vectors
    • Lentivirus
    • AAV
    • Adenovirus
    • Other vectors
    Our approach
    • Ways to work with us
    • Research and innovation
    New resources

    Visit our refreshed resource centre for the latest case studies, research posters and more.

    Visit the resource hub
  • Company
    About us
    • Who we are
    • Our people
    • Facilities
    • ESG
    News & events
    • News
    • Upcoming events
    Investors
    • Investors portal
    Careers
    • Careers portal
  • Resources
  • Get in touch
OXB_Logo_White
Platforms
  • LentiVector™ platform
  • inAAVate™ platform
  • AdenoVate™ platform
Quick links
  • Upcoming events
  • News
  • Ways to work with us
  • Investors
  • Careers portal
Corporate policies
  • Privacy Notice
  • Cookie Policy
  • Modern Slavery
  • Terms of Use
  • Integrity and Ethics

© 2026 Oxford Biomedica PLC. All Rights Reserved. | Company No. 03252665 | VAT No. GB 663 6533 21 | Website by Arttia Creative

  • Home
  • CDMO solutions
    • CDMO solutions
      • Process development
      • GMP manufacturing
      • Analytical methods
      • Regulatory support
    • Viral vectors
      • Lentivirus
      • Adeno-associated-virus-aav
      • Adenovirus
      • Other vectors
    • Our approach
      • Ways to work with us
      • Research and innovation
  • Company
    • About us
      • Who we are
      • Our people
      • Facilities
      • ESG
    • News & events
      • News
      • Upcoming events
    • Investors
      • Investors portal
    • Careers
  • Resources
  • Get in touch